Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Pacira Pharma (PCRX) Tops Q3 EPS by 15c
November 7, 2019 8:12 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.48, $0.15 better than the analyst estimate of $0.33. Revenue for the quarter came in at $104.7 million versus the consensus estimate of $105.28 million.
2019 Financial Guidance:
Pacira reiterated its full year 2019 financial guidance as... More
